Common Contracts
6 similar Registration Rights Agreement contracts by Xtant Medical Holdings, Inc., Bacterin International Holdings, Inc., Cryoport, Inc., Shift Technologies, Inc.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 2nd, 2021 • Shift Technologies, Inc. • Retail-auto dealers & gasoline stations • New York
Shift Technologies, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the initial purchasers (collectively, the “Initial Purchasers”) listed in Schedule I to the Purchase Agreement (as defined below), for whom J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as representatives, its 4.75% Convertible Senior Notes due 2026 (the “Notes”), upon the terms set forth in the Purchase Agreement by and among the Company and J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, dated May 24, 2021 (the “Purchase Agreement”). If a conversion of Notes occurs during the periods and subject to certain conditions set forth in the terms of the Notes, the Company may be required to deliver shares of common stock of the Company, $0.0001 par value per share (the “Common Stock”) to the converting holder. To induce the Initial Purchasers to enter into the Purchase Agreement and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 27th, 2020 • Cryoport, Inc. • Pharmaceutical preparations • New York
Cryoport, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the initial purchasers (collectively, the “Initial Purchasers”) listed in Schedule I to the Purchase Agreement (as defined below), for whom Jefferies LLC and SVB Leerink LLC are acting as representatives, its 3.00% Convertible Senior Notes due 2025 (the “Notes”), upon the terms set forth in the Purchase Agreement by and among the Company and Jefferies LLC and SVB Leerink LLC, dated May 20, 2020 (the “Purchase Agreement”). Upon a conversion of Notes at the option of the holder thereof, the Company will be required to deliver shares of common stock of the Company, $0.001 par value per share (the “Common Stock”). To induce the Initial Purchasers to enter into the Purchase Agreement and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the benefit of this registration rights agreement (this “Agreement”) pursuant to which the Company agrees with the Initial Purchasers for th
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 20th, 2017 • Xtant Medical Holdings, Inc. • Biological products, (no disgnostic substances) • New York
Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (the “Purchasers”) convertible senior notes due 2021 in the aggregate principal amount of $67,145.00 (the “Notes”), upon the terms set forth in the Securities Purchase Agreements among the Company, each of the Purchasers, dated January 16, 2017 (the “Purchase Agreements”). Upon a conversion of each Note at the option of the holder thereof, the Company will be required to deliver shares of common stock of the Company, $0.000001 par value per share (the “Common Stock”). To induce the Purchasers to enter into the Purchase Agreements and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the benefit of this registration rights agreement (this “Agreement”) pursuant to which the Company agrees with the Purchasers for the benefit of the Purchasers and for the benefit of the holders (the “Holder
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 20th, 2017 • Xtant Medical Holdings, Inc. • Biological products, (no disgnostic substances) • New York
Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (the “Purchasers”) convertible senior notes due 2021 in the aggregate principal amount of $1,560,000 (the “Notes”), upon the terms set forth in the Securities Purchase Agreements among the Company, each of the Purchasers, dated January 16, 2017 (the “Purchase Agreements”). Upon a conversion of each Note at the option of the holder thereof, the Company will be required to deliver shares of common stock of the Company, $0.000001 par value per share (the “Common Stock”). To induce the Purchasers to enter into the Purchase Agreements and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the benefit of this registration rights agreement (this “Agreement”) pursuant to which the Company agrees with the Purchasers for the benefit of the Purchasers and for the benefit of the holders (the “Holder
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 19th, 2016 • Xtant Medical Holdings, Inc. • Biological products, (no disgnostic substances) • New York
Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (the “Purchasers”) convertible senior notes due 2021 (the “Notes”), upon the terms set forth in the Securities Purchase Agreement among the Company, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, dated April 14, 2016 (the “Purchase Agreement”). Upon a conversion of each Note at the option of the holder thereof, the Company will be required to deliver shares of common stock of the Company, $0.000001 par value per share (the “Common Stock”). To induce the Purchasers to enter into the Purchase Agreement and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the benefit of this registration rights agreement (this “Agreement”) pursuant to which the Company agrees with the Purchasers for the benefit of the Purchasers and for the benefit of the holders (the “Holders”) fro
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 3rd, 2015 • Bacterin International Holdings, Inc. • Biological products, (no disgnostic substances) • New York
Bacterin International Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Leerink Partners LLC, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (the “Initial Purchasers”) its 6.00% Convertible Senior Notes due 2021 (the “Notes”), upon the terms set forth in the Purchase Agreement between the Company and Leerink Partners LLC, dated July 27, 2015, and the Securities Purchase Agreement among the Company, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, dated July 27, 2015 (such purchase agreement and securities purchase agreement, the “Purchase Agreements”). Upon a conversion of Notes at the option of the holder thereof, the Company will be required to deliver shares of common stock of the Company, $0.000001 par value per share (the “Common Stock”). To induce the Initial Purchasers to enter into the Purchase Agreements and to satisfy the Company’s obligations thereunder, the holders of the Notes will have the ben
